Acquisition of novel oncology delivery technology
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD TherapeuticsNew molecular platform to access intracellular targets across a broad range of tumor cell typesOpens up new range of therapeutic opportunities for difficult-to-treat cancers
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news